3.4.22.1 (1E,4E)-1-chloro-4-ethenyl-2-(trichloro-lambda4-tellanyl)hepta-1,4,6-trien-3-ol - 129490 3.4.22.1 (1R,2S)-2-([(8-hydroxy-5-nitroquinolin-7-yl)methyl]amino)cyclohexane-1-carboxylic acid - 204498 3.4.22.1 (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 2,3,6-trideoxy-3-[([[4-([N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-phenylalanyl-L-lysyl]amino)benzyl]oxy]carbonyl)amino]-a-L-lyxo-hexopyranoside a Phe-Lys-para-aminobenzyloxycarbonyl-doxorubicin prodrug-albumin 150380 3.4.22.1 (2(1H)-pyridinethionato-kappaS2)[2,6-bis[(mercapto-kappaS)methyl]pyridine-kappaN] oxorhenium(V) - 75436 3.4.22.1 (2E)-3-chloro-1-phenyl-2-(trichloro-lambda4-tellanyl)prop-2-en-1-ol - 160003 3.4.22.1 (2R,3R)-3-(((1S)-1-[(4-carbamimidamidobutyl)carbamoyl]-3-methylbutyl)carbamoyl)oxirane-2-carboxylic acid - 129448 3.4.22.1 (2R,3R)-3-(((1S)-3-methyl-1-[(3-methylbutoxy)carbonyl]butyl)carbamoyl)aziridine-2-carboxylic acid - 129481 3.4.22.1 (2S)-2-amino-N-[(1S)-2-(biphenyl-4-yl)-1-cyanoethyl]butanamide - 7042 3.4.22.1 (2S,3S)-3-(((1S)-1-[(4-([(benzyloxy)carbonyl]amino)butyl)carbamoyl]-3-methylbutyl)carbamoyl)oxirane-2-carboxylic acid - 129450 3.4.22.1 (2S,3S)-3-(((1S)-1-[(4-aminobutyl)carbamoyl]-3-methylbutyl)carbamoyl)oxirane-2-carboxylic acid - 129449 3.4.22.1 (2S,3S)-3-(((1S)-1-[(4-carbamimidamidobutyl)carbamoyl]-3-methylbutyl)carbamoyl)oxirane-2-carboxylic acid - 129442 3.4.22.1 (2S,3S)-3-(((1S)-1-[(7-aminoheptyl)carbamoyl]-3-methylbutyl)carbamoyl)oxirane-2-carboxylic acid - 129451 3.4.22.1 (2S,3S)-3-(((1S)-3-methyl-1-[(3-methylbutoxy)carbonyl]butyl)carbamoyl)aziridine-2-carboxylic acid - 129482 3.4.22.1 (2S,3S)-3-(((1S)-3-methyl-1-[(3-methylbutyl)carbamoyl]butyl)carbamoyl)oxirane-2-carboxylic acid - 129443 3.4.22.1 (2S,3S)-3-([(1S)-1-(benzylcarbamoyl)-3-methylbutyl]carbamoyl)oxirane-2-carboxylic acid - 129453 3.4.22.1 (2Z)-1,3-bis(2-methoxyphenyl)-4-(trichloro-lambda4-tellanyl)but-2-en-1-one - 58462 3.4.22.1 (2Z)-1,3-bis(4-ethoxyphenyl)-4-(trichloro-lambda4-tellanyl)but-2-en-1-one - 160006 3.4.22.1 (2Z)-1,3-bis(4-methoxyphenyl)-4-(trichloro-lambda4-tellanyl)but-2-en-1-one - 160005 3.4.22.1 (2Z)-1,3-diphenyl-4-(trichloro-llambda4-tellanyl)but-2-en-1-one - 160004 3.4.22.1 (3E)-2-bromo-3-(bromomethylidene)-2-(4-methoxyphenyl)-1-oxa-2l4-telluraspiro[3.5]nonane - 160012 3.4.22.1 (3E)-2-bromo-3-(bromomethylidene)-2-(4-methoxyphenyl)-1-oxa-2lambda4-telluraspiro[3.5]nonane - 129492 3.4.22.1 (3E)-2-chloro-3-(chloromethylidene)-2-(4-methoxyphenyl)-1-oxa-2l4-telluraspiro[3.5]nonane - 160011 3.4.22.1 (3E)-2-chloro-3-(chloromethylidene)-2-(4-methoxyphenyl)-1-oxa-2lambda4-telluraspiro[3.5]nonane irreversible inhibition 129491 3.4.22.1 (3E)-2-chloro-3-(chloromethylidene)-2-(4-methoxyphenyl)-1-oxa-2lambda4-telluraspiro[3.6]decane - 129493 3.4.22.1 (3E)-4-chloro-3-([(2Z)-4-methoxy-1-methylidenepenta-2,4-dien-1-yl](dimethyl)-lambda4-tellanyl)-2-methylbut-3-en-2-ol - 129489 3.4.22.1 (3E)-4-chloro-3-[dichloro(4-methoxyphenyl)-l4-tellanyl]-2-methylbut-3-en-2-ol - 160008 3.4.22.1 (5S)-5-([N-[(benzyloxy)carbonyl]-L-phenylalanyl]amino)-7-[(2,6-dimethylbenzoyl)oxy]-6-oxoheptan-1-aminium trifluoroacetate - 204686 3.4.22.1 (5S)-5-([N-[(benzyloxy)carbonyl]-L-phenylalany]amino)-6-oxo-7-[(2,4,6-trimethylbenzoyl)oxy]heptan-1-aminium trifluoroacetate - 206278 3.4.22.1 (acetatato-kO)[2-(1-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-5-yl-kN4)phenyl-kC1](pyridine)palladium(1+) - 160021 3.4.22.1 (acetatato-kO)[2-(1-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-5-yl-kN4)phenyl-kC1](triphenylphosphane)palladium(1+) - 160020 3.4.22.1 (acetato)(isopropylamine)(2-((2dimethylamino)-methyl)phenyl)Pd(II) - 75431 3.4.22.1 (benzyl[(8-hydroxy-5-nitroquinolin-7-yl)methyl]amino)acetonitrile - 204697 3.4.22.1 (chloro)(isopropylamine)(2-((2dimethylamino)methyl)phenyl)Pd(II) - 75430 3.4.22.1 (chloro)(pryidinyl)(2-((2dimethylamino)methyl)phenyl)Pd(II) - 75429 3.4.22.1 (chloro)[2,6-bis[(mercapto-kappaS)methyl]pyridine-kappaN1] oxorhenium(V) - 75435 3.4.22.1 (methanethiolato)[2,2'-(thio-kappaS)bis[ethanethiolato-kappaS]] oxorhenium(V) - 75439 3.4.22.1 (p-methoxyphenylthiolato-S)[2,2'-(thio-kappaS)bis[ethanethiolato-kappaS]] oxorhenium(V) - 75438 3.4.22.1 (p-methoxyphenylthiolato-S)[2,6-bis[(mercapto-kappaS)methyl]pyridine-kappaN] oxorhenium(V) - 10222 3.4.22.1 (S)-18-[(S)-2-([(benzyloxy)carbonyl]amino)-3-phenylpropanamido]-1-(4-iodo-1H-1,2,3-triazol-1-yl)-12,19-dioxo-3,6,9-trioxa-13-azaicosan-20-yl 2,4,6-trimethylbenzoate - 204728 3.4.22.1 (S)-20-[(S)-2-([(benzyloxy)carbonyl]amino)-3-phenylpropanamido]-1-(3-iodophenyl)-1,14,21-trioxo-5,8,11-trioxa-2,15-diazadocosan-22-yl 2,4,6-trimethylbenzoate - 204729 3.4.22.1 (S)-20-[(S)-2-([(benzyloxy)carbonyl]amino)-3-phenylpropanamido]-1-(4-iodophenyl)-1,14,21-trioxo-5,8,11-trioxa-2,15-diazadocosan-22-yl 2,4,6-trimethylbenzoate - 204730 3.4.22.1 (S)-3-[(S)-2-([(benzyloxy)carbonyl]amino)-3-phenylpropanamido]-7-(3-iodobenzamido)-2-oxoheptyl 2,4,6-trimethylbenzoate pH 6, 37°C, ki/Ki (sec-1M-1): 630 204735 3.4.22.1 (S)-3-[(S)-2-([(benzyloxy)carbonyl]amino)-3-phenylpropanamido]-7-[3-(3-iodophenyl)ureido]-2-oxoheptyl 2,4,6-trimethylbenzoate pH 6, 37°C, ki/Ki (sec-1M-1): 0.013 204736 3.4.22.1 (S)-3-[(S)-2-([(benzyloxy)carbonyl]amino)-3-phenylpropanamido]-7-[3-(4-iodophenyl)ureido]-2-oxoheptyl 2,4,6-trimethylbenzoate pH 6, 37°C, ki/Ki (sec-1M-1): 0.0035 204737 3.4.22.1 (S)-3-[(S)-2-([(benzyloxy)carbonyl]amino)-3-phenylpropanamido]-7-[6-(3-iodobenzamido)hexanamido]-2-oxoheptyl 2,4,6-trimethylbenzoate pH 6, 37°C, ki/Ki (sec-1M-1): 280 204738 3.4.22.1 (S)-3-[(S)-2-([(benzyloxy)carbonyl]amino)-3-phenylpropanamido]-7-[6-(4-iodo-1H-1,2,3-triazol-1-yl)hexanamido]-2-oxoheptyl 2,4,6-trimethylbenzoate - 204739 3.4.22.1 (S)-3-[(S)-2-([(benzyloxy)carbonyl]amino)-3-phenylpropanamido]-7-[6-(4-iodobenzamido)hexanamido]-2-oxoheptyl 2,4,6-trimethylbenzoate pH 6, 37°C, ki/Ki (sec-1M-1): 310 204740 3.4.22.1 (S)-3-[(S)-2-[(benzyloxycarbonyl)amino]-3-phenylpropanamido]-7-(6-[3-(3-iodophenyl)ureido]hexanamido)-2-oxoheptyl 2,4,6-trimethylbenzoate - 204733 3.4.22.1 (S)-3-[(S)-2-[(benzyloxycarbonyl)amino]-3-phenylpropanamido]-7-(6-[3-(4-iodophenyl)ureido]hexanamido)-2-oxoheptyl 2,4,6-trimethylbenzoate - 204734 3.4.22.1 (triethylphosphine)gold(I) chloride - 66533 3.4.22.1 ([(8-hydroxy-5-nitroquinolin-7-yl)methyl](methyl)amino)acetonitrile - 204747 3.4.22.1 ([(8-hydroxy-5-nitroquinolin-7-yl)methyl]amino)acetonitrile best performing inhibitor is effective in cell-based in vitro models of tumor invasion, where it significantly abrogates invasion of MCF-10A neoT cells 206277 3.4.22.1 1,1'-[[3-(5-nitroquinolin-8-yl)furan-2,5-diyl]dibenzene-4,1-diyl]diethanone - 234991 3.4.22.1 1,1,3-trichloro-2,4,5,6-tetrahydro-1H-1-benzotellurophene - 160014 3.4.22.1 1,10-phenanthroline 66% remaining activity at 1 mM, 68% remaining activity at 2 mM 62 3.4.22.1 1,10-phenanthroline 77.3% residual activity at 1 mM 62 3.4.22.1 1,3,5-triphenyl pyrazole - 204752 3.4.22.1 1,3,5-triphenyl-2-pyrazoline - 204753 3.4.22.1 1-(3-chlorophenyl)-3-[1-[(2-cyanotetrahydropyridazin-1(2H)-yl)carbonyl]-2-methylpropyl]urea - 26114 3.4.22.1 1-(4-chlorophenyl)-3-[1-[(2-cyanotetrahydropyridazin-1(2H)-yl)carbonyl]-2-methylpropyl]urea - 26115 3.4.22.1 1-(4-cyanophenyl)-3-[1-[(2-cyanotetrahydropyridazin-1(2H)-yl)carbonyl]-2-methylpropyl]urea - 26116 3.4.22.1 1-(4-nitronaphthalen-1-yl)pyrrolidine - 204801 3.4.22.1 1-(dichloro[(1E)-1-chloro-3-methoxyprop-1-en-2-yl]-l4-tellanyl)-4-methoxybenzene - 160007 3.4.22.1 1-(dichloro[(1Z,3E,5Z)-2-chloroocta-1,3,5,7-tetraen-1-yl]-lambda4-tellanyl)-4-methoxybenzene - 129494 3.4.22.1 1-(dichloro[(Z)-2-chloro-2-phenylethenyl]-l4-tellanyl)-4-methoxybenzene bis-vinylic organotellurane, can be a candidate as a starting compound to design more efficient and specific inhibitors for cathepsin B 160009 3.4.22.1 1-tosylamide-2-phenylethyl chloromethylketone - 16316 3.4.22.1 1-tosylamide-2-phenylethyl chloromethylketone moderate effect 16316 3.4.22.1 1-[1-[(2-cyanotetrahydropyridazin-1(2H)-yl)carbonyl]-2-methylpropyl]-3-(3-methylphenyl)urea - 26121 3.4.22.1 1-[1-[(2-cyanotetrahydropyridazin-1(2H)-yl)carbonyl]-2-methylpropyl]-3-phenylurea - 26122 3.4.22.1 1-[1-[(2-cyanotetrahydropyridazin-1(2H)-yl)carbonyl]-2-methylpropyl]-3-[3-(trifluoromethyl)phenyl]urea - 26123 3.4.22.1 1-[4-[3-(5-nitroquinolin-8-yl)furan-2-yl]phenyl]ethan-1-one - 234990 3.4.22.1 1-[N-(tert-butoxycarbonyl)-L-phenylalanyl]-3-(ethoxycarbonyl)aziridine-2-carboxylic acid - 129471 3.4.22.1 1-[N-(tert-butoxycarbonyl)-L-phenylalanyl]aziridine-2,3-dicarboxylic acid - 129472 3.4.22.1 2,12-diethyl-11-methylhexadecyl 2-ethyl-11-methylhexadecyl phthalate isolated from seahorse, Hippocampus Kuda Bleeker, NMR structure determination and analysis, overview 72949 3.4.22.1 2,2'-dipyridyl disulfide - 7087 3.4.22.1 2-(3-chloro-4-fluorophenyl)-1,2-thiazol-3(2H)-one - 86187 3.4.22.1 2-bromo-4-nitronaphthalen-1-amine - 204955 3.4.22.1 2-chlorobenzohydrazide competitive inhibition 201799 3.4.22.1 2-ethyldecyl 2-ethylundecyl phthalate isolated from seahorse, Hippocampus Kuda Bleeker, NMR structure determination and analysis, overview 73048 3.4.22.1 2-methoxybenzohydrazide competitive inhibition 201795 3.4.22.1 2-methyl-5-nitroquinolin-8-ol - 234985 3.4.22.1 2-naphthyl-alanine - 239851 3.4.22.1 2-pentyl-1,2-thiazol-3(2H)-one - 86189 3.4.22.1 2-phenylisothiazol-3(2H)-one - 19058 3.4.22.1 2-[(6-([3'-(aminomethyl)biphenyl-3-yl]oxy)-3,5-difluoropyridin-2-yl)oxy]benzoic acid - 160010 3.4.22.1 2A2 monoclonal antibody binds to the epitope EPGYSP sequence, i.e. in the nonapeptide CIAEPGYSP, that is located between amino acid residues 133-138 of cathepsin B in the proximity of the occluding loop, surface plasmon resonance analysis, overview. Binding of 2A2 monoclonal antibody to the cathepsin B/cystatin C complex causes the dissociation of cystatin C from the complex, and binding of the antibody induces a conformational change in cathepsin B, stabilizing its exopeptidase conformation and thus disabling its harmful action associated with its endopeptidase activity 40413 3.4.22.1 3,5-diphenyl-2-pyrazoline - 205015 3.4.22.1 3,5-diphenyl-4-amino-1,2,4-triazole non-competitive inhibition 201800 3.4.22.1 3-(([(3S)-3-((N-[(4-chloro-2-fluorophenyl)carbonyl]-3-methyl-L-phenylalanyl)amino)-3-cyanopropyl]oxy)methyl)benzoic acid IC50: 0.000002 mM 58454 3.4.22.1 3-(([(3S)-3-cyano-3-([3-methyl-N-(phenylcarbonyl)-L-phenylalanyl]amino)propyl]oxy)methyl)benzoic acid IC50: 0.0000094 mM 58455 3.4.22.1 3-(([(3S)-3-cyano-3-([N-(diphenylacetyl)-3-methyl-L-phenylalanyl]amino)propyl]oxy)methyl)benzoic acid IC50: 0.0000018 mM 58451 3.4.22.1 3-(2-hydroxy-3-methylphenyl)-5-(2-hydroxy-3-methylphenyl)-4-amino-1,2,4-triazole non-competitive inhibition 205036 3.4.22.1 3-(2-methylphenyl)-5-(2-methylphenyl)-4-amino-1,2,4-triazole non-competitive inhibition 205037 3.4.22.1 3-(3-aminophenyl)-5-(3-aminophenyl)-4-amino-1,2,4-triazole non-competitive inhibition 205040 3.4.22.1 3-(3-methylphenyl)-5-(3-methylphenyl)-4-amino-1,2,4-triazole non-competitive inhibition 205041 3.4.22.1 3-(4-chlorophenyl)-5-(4-chlorophenyl)-4-amino-1,2,4-triazole non-competitive inhibition 205044 3.4.22.1 3-(4-methylphenyl)-5-(4-methylphenyl)-4-amino-1,2,4-triazole non-competitive inhibition 205045 3.4.22.1 3-(N-benzyloxycarbonylphenylalanylamido)-DL-1-fluoro-2-butanone irreversible covalent inhibitor 239840 3.4.22.1 3-([(2R)-2-cyano-2-([3-methyl-N-(2-methyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-L-phenylalanyl]amino)ethoxy]methyl)benzoic acid IC50: 0.0000049 mM 58458 3.4.22.1 3-([(2R)-2-cyano-2-([3-methyl-N-(3-oxo-2,3-dihydro-1H-inden-5-yl)-L-phenylalanyl]amino)ethoxy]methyl)benzoic acid IC50: 0.0000053 mM 58456 3.4.22.1 3-([(2R)-2-cyano-2-([N-(1,1-dimethyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-3-methyl-L-phenylalanyl]amino)ethoxy]methyl)benzoic acid IC50: 0.0000053 mM 58457 3.4.22.1 3-methylbutyl N-[(3-methoxy-1,2,4-thiadiazolidin-5-yl)carbamoyl]-L-leucyl-L-prolinate IC50: 0.367 mM 58429 3.4.22.1 3-phenyl-5-(3-nitrophenyl)-4-amino-1,2,4-triazole non-competitive inhibition 205075 3.4.22.1 3-phenyl-5-(4-nitrophenyl)-4-amino-1,2,4-triazole non-competitive inhibition 205076 3.4.22.1 3-[(5S)-5-cyano-5-([N-(diphenylacetyl)-3-methyl-L-phenylalanyl]amino)pentyl]benzoic acid IC50: 0.000018 mM 58452 3.4.22.1 4'''-methylamentoflavone IC50: 0.00168 mM 58421 3.4.22.1 4-(([(3S)-3-cyano-3-([N-(diphenylacetyl)-3-methyl-L-phenylalanyl]amino)propyl]oxy)methyl)benzoic acid IC50: 0.000005 mM 58453 3.4.22.1 4-(4-nitronaphthalen-1-yl)morpholine - 205133 3.4.22.1 4-bromochalcone phenyl hydrazone - 205162 3.4.22.1 4-chlorochalcone phenyl hydrazone - 205171 3.4.22.1 4-hydroxy-2-nonenal 0.015 mM, 76% loss of activity, formation of Michael adducts with C29 of A chain and H150 of B chain 1426 3.4.22.1 4-hydroxybenzohydrazide competitive inhibition 201797 3.4.22.1 4-methoxy-3-(3-methoxypropoxy)-1-(5-nitroquinolin-8-yl)pyridin-1-ium - 234989 3.4.22.1 4-methoxybenzohydrazide competitive inhibition 201796 3.4.22.1 4-methoxychalcone phenyl hydrazone - 205190 3.4.22.1 4-methylchalcone phenyl hydrazone - 205191 3.4.22.1 4-nitro-L-phenylalanine inactivation rate is 3.0 mM/min 11782 3.4.22.1 4-nitrochalcone phenyl hydrazone - 205193 3.4.22.1 4-nitronaphthalen-1-amine - 205194 3.4.22.1 4-nitronaphthalen-1-ol - 205195 3.4.22.1 5,5'-dithiobis-2-nitrobenzoic acid - 5368 3.4.22.1 5,7-dihydroxy-2-(4-hydroxy-3-[7-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-8-yl]phenyl)-4H-chromen-4-one IC50: 0.00175 mM 58420 3.4.22.1 5,7-dihydroxy-2-(4-hydroxy-3-[7-hydroxy-2-(4-methoxyphenyl)-4-oxo-4H-chromen-8-yl]phenyl)-4H-chromen-4-one IC50: 0.00168 mM 58422 3.4.22.1 5,7-dihydroxy-2-(4-hydroxy-3-[7-methoxy-2-(4-methoxyphenyl)-4-oxo-4H-chromen-8-yl]phenyl)-4H-chromen-4-one IC50: 0.00055 mM 58423 3.4.22.1 5,7-dinitroquinolin-8-ol - 205230 3.4.22.1 5-(((2R)-2-cyano-2-[(3-methyl-N-phenyl-L-phenylalanyl)amino]ethoxy)methyl)-2-fluorobenzoic acid IC50: 0.0000122 mM 58461 3.4.22.1 5-(4-bromophenyl)-1,3-diphenyl pyrazole - 205253 3.4.22.1 5-(4-bromophenyl)-1,3-diphenyl-2-pyrazoline - 205254 3.4.22.1 5-(4-bromophenyl)-3-phenyl-2-pyrazoline - 205255 3.4.22.1 5-(4-chlorophenyl)-1,3-diphenyl pyrazole - 205256 3.4.22.1 5-(4-chlorophenyl)-1,3-diphenyl-2-pyrazoline - 205257 3.4.22.1 5-(4-chlorophenyl)-3-phenyl-2-pyrazoline - 205258 3.4.22.1 5-(4-methoxyphenyl)-1,3-diphenyl pyrazole - 205267 3.4.22.1 5-(4-methoxyphenyl)-1,3-diphenyl-2-pyrazoline - 205268 3.4.22.1 5-(4-methoxyphenyl)-3-phenyl-2-pyrazoline - 205269 3.4.22.1 5-(4-methylphenyl)-1,3-diphenyl pyrazole - 205270 3.4.22.1 5-(4-methylphenyl)-1,3-diphenyl-2-pyrazoline - 205271 3.4.22.1 5-(4-methylphenyl)-3-phenyl-2-pyrazoline - 205272 3.4.22.1 5-(4-nitrophenyl)-1,3-diphenyl pyrazole - 205273 3.4.22.1 5-(4-nitrophenyl)-1,3-diphenyl-2-pyrazoline - 205274 3.4.22.1 5-(4-nitrophenyl)-3-phenyl-2-pyrazoline - 205275 3.4.22.1 5-([(2R)-2-cyano-2-([3-methyl-N-(3-oxo-1,3-dihydro-2-benzofuran-5-yl)-L-phenylalanyl]amino)ethoxy]methyl)-2-fluorobenzoic acid IC50: 0.0000041 mM 58460 3.4.22.1 5-amino-1-(phenylsulfonyl)-1H-pyrazol-3-yl thiophene-2-carboxylate - 36819 3.4.22.1 5-amino-1-[(4-fluorophenyl)sulfonyl]-1H-pyrazol-3-yl furan-2-carboxylate - 64727 3.4.22.1 5-amino-1-[(4-fluorophenyl)sulfonyl]-1H-pyrazol-3-yl thiophene-2-carboxylate - 64728 3.4.22.1 5-amino-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrazol-3-yl thiophene-2-carboxylate - 64729 3.4.22.1 5-amino-1-[(4-methylphenyl)sulfonyl]-1H-pyrazol-3-yl furan-2-carboxylate - 64730 3.4.22.1 5-amino-1-[(4-methylphenyl)sulfonyl]-1H-pyrazol-3-yl thiophene-2-carboxylate - 64731 3.4.22.1 5-chloro-2-(2-chloro-4,5-dimethoxyphenethyl)isothiazol-3(2H)-one - 86449 3.4.22.1 5-chloro-2-(3-chloro-4-fluorophenyl)-1,2-thiazol-3(2H)-one - 86188 3.4.22.1 5-chloro-2-pentyl-1,2-thiazol-3(2H)-one - 86190 3.4.22.1 5-chloro-2-phenylisothiazol-3(2H)-one - 86447 3.4.22.1 5-nitro-7-((4-[(pyridin-3-yl)methyl]piperazin-1-yl)methyl)quinolin-8-ol - 205308 3.4.22.1 5-nitro-7-((4-[(pyridin-4-yl)methyl]piperazin-1-yl)methyl)quinolin-8-ol - 205309 3.4.22.1 5-nitro-N-[(pyridin-2-yl)methyl]quinolin-8-amine - 205310 3.4.22.1 7'',4'''-dimethylamentoflavone IC50: 0.00055 mM 60863 3.4.22.1 7-([(2R)-2-methylpiperidin-1-yl]methyl)-5-nitroquinolin-8-ol - 205380 3.4.22.1 7-epiclusianone a prenylated benzophenone isolated from pericarp hexane extract of dried fruits of Rheedia brasiliensis 160029 3.4.22.1 7-[(benzylamino)methyl]-5-nitroquinolin-8-ol - 205383 3.4.22.1 7-[(ethylamino)methyl]-5-nitroquinolin-8-ol - 205384 3.4.22.1 8-(4-methylpiperidin-1-yl)-5-nitroquinoline - 205385 3.4.22.1 8-(morpholin-4-yl)-5-nitroquinoline - 205386 3.4.22.1 8-hydroxy-5-nitroquinoline-2-carbonitrile - 234986 3.4.22.1 8-hydroxy-5-nitroquinoline-7-carboxylic acid - 205387 3.4.22.1 aceto[2,6-bis[(butylthio-kappaS)methyl]phenyl-kappaC]-,(SP-4-3)Pd(II) - 75433 3.4.22.1 aceto[2,6-bis[(methylthio-kappaS)methyl]phenyl-kappaC]-,(SP-4-3)Pd(II) - 75432 3.4.22.1 aceto[2,6-bis[(phenylthio-kappaS)methyl]phenyl-kappaC]-, (SP-4-3)Pd(II) - 75434 3.4.22.1 acetyl-Asp-Glu-Val-Asp-CHO complete DEVDase activity inhibition in brain cell supernatant 151608 3.4.22.1 acetyl-DEVD-CHO - 22270 3.4.22.1 acetyl-Leu-Ile-arginal IC50: 0.00015 mM 58439 3.4.22.1 acetyl-Leu-Leu-lysinal IC50: 0.00013 mM 58442 3.4.22.1 acetyl-Leu-Phe-arginal IC50: 0.0011 mM 58440 3.4.22.1 acetyl-Leu-Phe-lysinal IC50: 0.0001 mM 58443 3.4.22.1 acetyl-Leu-Val-lysinal IC50: 0.000004 mM 35405 3.4.22.1 acetyl-LVK-CHO - 139076 3.4.22.1 acetyl-Phe-Val-arginal IC50: 0.000039 mM 58441 3.4.22.1 acetyl-YVAD-chloromethyl ketone caspase inhibitor, inhibition of enzyme contributes to neuroprotective properties of the inhibitor 54327 3.4.22.1 AEBSF 0.2 mM, partial inhibition; 0.2 mM, partial inhibition; 0.2 mM, partial inhibition; 0.2 mM, partial inhibition 13510 3.4.22.1 AM4299A irreversible inhibition, IC50: 0.000073 mM 60846 3.4.22.1 AM4299B irreversible inhibition, IC50: 0.000130 mM 60847 3.4.22.1 amentoflavone IC50: 0.00175 mM 4391 3.4.22.1 AMF1 - 132493 3.4.22.1 AMF2 - 132494 3.4.22.1 AMF3 - 132495 3.4.22.1 AMF4 IC50: 0.00062 mM 60864 3.4.22.1 AMF5 - 132496 3.4.22.1 ammonium 1-tribromo-1,3,2-dioxatellurolane - 81052 3.4.22.1 ammonium 1-trichloro-1,3,2-dioxatellurolane - 81051 3.4.22.1 ankyrin repeat protein i.e. DARPin 8h6 239846 3.4.22.1 antipain - 520 3.4.22.1 antipain 93% inhibition at 1 microM 520 3.4.22.1 antipain complete inhibition at 1 mM 520 3.4.22.1 APC-3316 kinetics, pH-dependence of inhibition 117956 3.4.22.1 APC-5840 kinetics, pH-dependence of inhibition 117954 3.4.22.1 APC-8754 kinetics, pH-dependence of inhibition 117955 3.4.22.1 arsenite i.e. arsenic trioxide, inhibits CatB in glioblastoma cells, 20% inhibition at 0.022 mM, 50% at 0.020 mM 397 3.4.22.1 auranofin competitive, reversible inhibitor of cathepsin B 1894 3.4.22.1 bafilomycin - 32152 3.4.22.1 bafilomycin A1 - 6127 3.4.22.1 bafilomycin A1 100 nM significantly inhibits activity 6127 3.4.22.1 benzyl N-(3-methoxy-1,2,4-thiadiazolidin-5-yl)-L-alanyl-L-phenylalaninate IC50: 0.037 mM 58431 3.4.22.1 benzyl N-([(2R,3R)-3-(butoxycarbonyl)oxiran-2-yl]carbonyl)-L-leucyl-L-prolinate - 129465 3.4.22.1 benzyl N-([(2R,3R)-3-(ethoxycarbonyl)aziridin-2-yl]carbonyl)-L-leucinate - 129479 3.4.22.1 benzyl N-([(2R,3R)-3-(ethoxycarbonyl)aziridin-2-yl]carbonyl)-L-leucyl-L-prolinate - 129473 3.4.22.1 benzyl N-([(2R,3R)-3-(ethoxycarbonyl)oxiran-2-yl]carbonyl)-L-leucyl-L-prolinate - 129460 3.4.22.1 benzyl N-([(2R,3R)-3-carboxyoxiran-2-yl]carbonyl)-L-leucyl-L-prolinate - 129458 3.4.22.1 benzyl N-([(2S,3S)-3-(ethoxycarbonyl)aziridin-2-yl]carbonyl)-L-leucinate - 129480 3.4.22.1 benzyl N-([(2S,3S)-3-carboxyoxiran-2-yl]carbonyl)-L-leucyl-L-prolinate - 129459 3.4.22.1 benzyl N-[(3-carboxyaziridin-2-yl)carbonyl]-L-leucyl-L-prolinate - 129474 3.4.22.1 benzyl [(1R)-1-((1-[hydroxy(3-oxo-2-phenylcycloprop-1-en-1-yl)methyl]-2-methylpropyl)carbamoyl)-2-methylpropyl]carbamate IC50: 0.000044 mM 58445 3.4.22.1 benzyl [(1R)-1-((1-[hydroxy(3-oxo-2-phenylcycloprop-1-en-1-yl)methyl]-4-methylpentyl)carbamoyl)-2-methylpropyl]carbamate IC50: 0.0290 mM 58448 3.4.22.1 benzyl [(1R)-1-([1-benzyl-2-hydroxy-2-(3-oxo-2-phenylcycloprop-1-en-1-yl)ethyl]carbamoyl)-2-methylpropyl]carbamate IC50: more than 0.1 mM 58449 3.4.22.1 benzyl [(1R)-1-([2-hydroxy-1-methyl-2-(3-oxo-2-phenylcycloprop-1-en-1-yl)ethyl]carbamoyl)-2-methylpropyl]carbamate IC50: 0.0229 mM 58446 3.4.22.1 benzyl [(1R)-2-((1-[hydroxy(3-oxo-2-phenylcycloprop-1-en-1-yl)methyl]-2-methylpropyl)amino)-1-methyl-2-oxoethyl]carbamate IC50: 0.00945 mM 58447 3.4.22.1 benzyl [(1S)-1-((1-[hydroxy(3-oxo-2-phenylcycloprop-1-en-1-yl)methyl]-2-methylpropyl)carbamoyl)-2-methylpropyl]carbamate IC50: 0.00071 mM 58444 3.4.22.1 benzylamido-L-trans-epoxysuccinyl-Ile-O-benzyl ester - 81107 3.4.22.1 benzylamido-L-trans-epoxysuccinyl-Ile-Pro-OH - 81104 3.4.22.1 benzyloxycarbonyl-Arg-Ser-chloromethylketone - 100222 3.4.22.1 benzyloxycarbonyl-FA-fmk - 139075 3.4.22.1 benzyloxycarbonyl-FGNHO-Bz - 139077 3.4.22.1 benzyloxycarbonyl-L-Phe-Ala-fluoromethyl ketone specific inhibitor 139081 3.4.22.1 benzyloxycarbonyl-L-phenylalanyl-alanine-fluoromethylketone inhibits cathepsin B, treatment stimulates proliferation of type-II pneumocytes and improves degenerative alterations in injured lung occurring with liver injury induced by D-GalN/TNF-alpha, overview 160028 3.4.22.1 benzyloxycarbonyl-L-phenylalanyl-L-phenylalanyl diazomethyl ketone irreversible covalent inhibitor 239844 3.4.22.1 benzyloxycarbonyl-Leu-Leu-Tyr-CHN2 - 31407 3.4.22.1 Benzyloxycarbonyl-Phe-Ala-CHN2 - 8055 3.4.22.1 benzyloxycarbonyl-phenylalanyl diazomethyl ketone irreversible covalent inhibitor 239843 3.4.22.1 benzyloxycarbonyl-Trp-Met-CHN2 - 47128 3.4.22.1 biotin-NH-(CH2)6-NH-Gly-Gly-L-Leu(2S,3S)-trans-epoxysuccinyl-L-Leu-L-Pro-OH selective for cathepsin B over cathepsin L 117968 3.4.22.1 bis(2-ethyldodecyl) phthalate isolated from seahorse, Hippocampus Kuda Bleeker, NMR structure determination and analysis, overview 73478 3.4.22.1 bis(2-ethylheptyl) phthalate isolated from seahorse, Hippocampus Kuda Bleeker, NMR structure determination and analysis, overview 73479 3.4.22.1 Bz-Phe-Arg-CH2F irreversible covalent inhibitor 239842 3.4.22.1 BzlNH-tES-Ile-Pro-OBzl - 66548 3.4.22.1 BzlNH-tES-Ile-Pro-OH - 66545 3.4.22.1 CA-030 and derivatives 239837 3.4.22.1 CA-074 - 5355 3.4.22.1 CA-074 specific inhibitor 5355 3.4.22.1 CA-074 0.0005 mM 5355 3.4.22.1 CA-074 a cathepsin B-specific inhibitor, inhibition CmCatB1 5355 3.4.22.1 CA-074 0.001 mM 5355 3.4.22.1 CA-074 irreversible cathepsin B inhibitor 5355 3.4.22.1 CA-074 cathepsin B-specific inhibitor 5355 3.4.22.1 CA-074 a selective cell-impermeable cathepsin B inhibitor 5355 3.4.22.1 CA-074 a cathepsin B inhibitor 5355 3.4.22.1 CA-074 a cathepsin B inhibitor significantly attenuates the ratio of hypodiploid and apoptotic cells, partially blocks caspase 3 activation and inhibits reduction of cell viability induced by emodin 5355 3.4.22.1 CA-074 cathepsin B inhibitor III, i.e. [L-3-trans-(propylcarbamoyl)oxirane-2-carbonyl]-L-isoleucyl-L-proline 5355 3.4.22.1 CA-074 and derivatives 5355 3.4.22.1 CA-074 i.-e. [L-3-trans-(propylcarbamoyl)oxirane-2-carbonyl]-L-isoleucyl-L-proline and its derivates, irreversible covalent inhibitor 5355 3.4.22.1 CA-074 0.01 mM, 97% loss of activity 5355 3.4.22.1 CA-074 Me - 35833 3.4.22.1 CA-074 Me 99.4% inhibition at 0.010 mM in cell lysates 35833 3.4.22.1 CA-074 Me a specific cathepsin B inhibitor 35833 3.4.22.1 Ca-074 methyl ester - 139074 3.4.22.1 Ca-074 methyl ester 0.001 mM, complete inhibition; 0.001 mM, complete inhibition; 0.001 mM, complete inhibition; 0.001 mM, complete inhibition 139074 3.4.22.1 CA-074-Me - 3935 3.4.22.1 CA-074-Me Cat B-selective inhibitor 3935 3.4.22.1 CA-074-Me suppresses microglia conditioned culture medium-induced glioma cell death 3935 3.4.22.1 CA-074-Me strong inhibition 3935 3.4.22.1 CA-074-Me CA-074Me clearly inhibits cath-B expression in the subcutaneous heteroplastic pancreatic carcinoma model, and demonstrates an anti-neoplastic and anti-angiogenesis effect, overview 3935 3.4.22.1 CA-074-Me i.e. propylcarbonyl-L-trans-epoxysuccinyl-Ile-Pro-OH, enzyme binding structure at the active site cleft, modelling, overview 3935 3.4.22.1 CA-074-Me a specific inhibitor, inhibits pro-interleukin-1beta processing in microglia 3935 3.4.22.1 CA-074-Me cathepsin B inhibition decreases hepatic stellate cell proliferation and the expression of phenotypic markers of hepatic stellate cell activation, and it down-regulate alpha-smooth musle actin mRNA and protein levels in LX2 cells, overview. Reduction of CtsB and/or CtsD levels by siRNA decreases cell proliferation, compared to control siRNA-transfected LX2 cells 3935 3.4.22.1 CA-074-Me a potent and specific CtsB inhibitor, CtsB inhibition blunts AKT phosphorylation in activated hepatic stellate cells in response to platelet-derived growth factor 3935 3.4.22.1 CA-074-Me cathepsin B inhibitor IV. Inhibition of cathepsin B blocks MEK1 cleavage induced by anthrax lethal toxin through delaying LeTx release into the cytoplasm. The cathepsin B inhibitor prevents cell death induced by anthrax lethal toxin in RAW 264.7 macrophages 3935 3.4.22.1 CA-074-Me i.e. [L-3-trans-(propylcarbamoyl)oxirane-2-carbonyl]-L-isoleucyl-L-proline methyl ester 3935 3.4.22.1 CA-074-Me in vivo inhibition 3935 3.4.22.1 CA-074-OMe blocks cysteine cathepsins in addition to CatB in in primary human antigen-presenting cells 160025 3.4.22.1 CA-074Me - 5004 3.4.22.1 CA-074Me a specific inhibitor for cathepsin B 5004 3.4.22.1 CA-074Me a selective cell-permeable cathepsin B inhibitor 5004 3.4.22.1 CA-074Me a cathepsin B inhibitor 5004 3.4.22.1 CA-074Me cathepsin B specific inhibitor, cathepsin B inhibitor IV, i.e. [L-3-trans-(propylcarbamoyl)oxirane-2-carbonyl]-L-isoleucyl-L-proline methyl ester 5004 3.4.22.1 CA028 irreversible inhibition, IC50: 0.000140 mM 60845 3.4.22.1 CA030 irreversible inhibition, IC50: 0.00000438 mM 18064 3.4.22.1 CA030 - 18064 3.4.22.1 CA030 i.e. ethoxy-L-trans-epoxysuccinyl-Ile-Pro-OH 18064 3.4.22.1 CA074 kinetic analysis 4358 3.4.22.1 CA074 - 4358 3.4.22.1 CA074 high specificity, 34000fold more effective on enzyme than on cathepsin X 4358 3.4.22.1 CA074 irreversible inhibition, IC50: 0.00000194 mM 4358 3.4.22.1 CA074 an irreversible CB inhibitor 4358 3.4.22.1 CA074 treatment of colorectal cancer cells cells with the cathepsin B inhibitor Ca074 leads to invasiveness of human CRC cells 4358 3.4.22.1 CA074Me inhibition affects myotube size and number, fusion-related creatine phosphokinase activity and myosin heavy chain protein, inhibition occurs at each stage of differentiation 17268 3.4.22.1 CA074Me - 17268 3.4.22.1 CA074Me cathepsin B specific inhibitor 17268 3.4.22.1 Ca2+ 40% inhibition at 2 mM 15 3.4.22.1 CAA0445 noncovalent-type, specific 118019 3.4.22.1 Cabin-1 i.e. LGPVTQE, peptide from human apolipoproteinA-1, 50% inhibition at 0.45 mM 117961 3.4.22.1 Cabin-2 i.e. VLQSSGLYS, peptide from human immunoglobulin G gamma chain, 50% inhibition at 0.5 mM 117962 3.4.22.1 Cabin-2(1-8) i.e. VLQSSGLY, peptide from human immunoglobulin G gamma chain, 50% inhibition at 0.004 mM 117963 3.4.22.1 Cabin-3 i.e. VVSVLT, peptide from human immunoglobulin G gamma chain, 50% inhibition at 0.02 mM 117964 3.4.22.1 Cabin-4 i.e. LVYDAY, peptide from human transferrin, 50% inhibition at 0.0005 mM 117965 3.4.22.1 Cabin-A1 i.e. SLHTLF, peptide derived from human serum albumin 54328 3.4.22.1 Cabin-A2 i.e. FQNAL, peptide derived from human serum albumin 54329 3.4.22.1 canecystatin-1 - 86442 3.4.22.1 canecystatin-4 - 86443 3.4.22.1 carbobenzoxy-Phe-NH-CH2CN reversible, 50% inhibition at 0.062 mM 117957 3.4.22.1 cathepsin B inhibitor III i.e. L-trans.epoxysuccinyl(propylamide)-Ile-Pro or 1-[3-methyl-2-[[3-(propylcarbamoyl)oxirane]-2-carbonyl]amino]pentanoylpyrrolidine-2-carboxylic acid 151606 3.4.22.1 cathepsin B inhibitor IV i.e. CA074me or methyl 1-[3-methyl-2-[[3-(propylcarbamoyl)oxirane]-2-carbonyl]amino]pentanoylpyrrolidine-2-carboxylate, bone marrow-derived macrophages treated with the cathepsin B-specific chemical inhibitor CA074 methyl ester secret significantly less TNF-alpha than wild-type or nontreated macrophages 151607 3.4.22.1 cathestatin A irreversible inhibition, IC50: 0.000260 mM 60850 3.4.22.1 cathestatin B irreversible inhibition, IC50: 0.000280 mM 60851 3.4.22.1 cathestatin C irreversible inhibition, IC50: 0.000114 mM 60852 3.4.22.1 CBZ-Phe-Ser(OBzl)-CHN2 cysteine protease inhibitor 1 (CP-1), effective inhibition at 0.05 mM 139072 3.4.22.1 Cd2+ - 52 3.4.22.1 chagasin an inhibitor from Trypanosoma cruzi, Three residues from chagasin, Leu65, Gly66, and Ala67, interact with cathepsin B residues Gly74, Gly73, and Asn72, binding mode and structure of wild-type enzyme and non-glycosylated S115A and H110A/S115A cathepsin B mutants, modeling, overview 7723 3.4.22.1 chalcone phenyl hydrazone - 205407 3.4.22.1 chicken cystatin - 4082 3.4.22.1 chloro(diethylphenylphosphine)gold(I) - 66534 3.4.22.1 chloro(ethyldiphenylphosphine)gold(I) - 66535 3.4.22.1 chloro(triphenylphosphine)gold(I) - 25055 3.4.22.1 chloro(tris(p-fluorophenyl)phosphine)gold(I) - 67018 3.4.22.1 chloro-[2,2'-(thio-kappaS)bis[ethanethiolato-kappaS]] oxorhenium(V) - 75437 3.4.22.1 Chloroquine - 1439 3.4.22.1 chloro[2-(1-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-5-yl-kN4)phenyl-kC1](pyridine)palladium(1+) - 160019 3.4.22.1 chloro[2-(1-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-5-yl-kN4)phenyl-kC1](triphenylphosphane)palladium(1+) - 160018 3.4.22.1 chloro[4-(diphenylphosphino-kappaP)benzenamine]gold(I) - 66024 3.4.22.1 chloro[4-(diphenylphosphino-kappaP)benzoato]gold(I) - 66025 3.4.22.1 chloro[diphenyl(phenylmethyl)phosphine]gold(I) - 66537 3.4.22.1 chloro[diphenyl[4-(2-phenyl-1,3-dioxolan-2-yl)phenyl]phosphine-kappaP]gold(I) - 57324 3.4.22.1 chloro[N-[2-(diphenylphosphino-kappaP)ethyl]benzamide]gold(I) - 66021 3.4.22.1 chloro[N-[2-(diphenylphosphino-kappaP)ethyl]benzeneacetamide]gold(I) - 66022 3.4.22.1 chloro[N-[2-(diphenylphosphino-kappaP)ethyl]benzenepropanamide]gold(I) - 66023 3.4.22.1 chloro[tris(p-methoxyphenyl)phosphine]gold(I) - 66536 3.4.22.1 chloro[tris(pentafluorophenyl)phosphine]gold(I) - 67019 3.4.22.1 chloro[[1,1'-biphenyl]-4-yldiphenylphosphine]gold(I) - 66538 3.4.22.1 chymostatin 85% inhibition at 5 microM 511 3.4.22.1 chymostatin - 511 3.4.22.1 chymostatin 80% inhibition at 6 microM 511 3.4.22.1 chymostatin 0.1 mM, 96% loss of activity 511 3.4.22.1 CID 11834381 - 81092 3.4.22.1 CID 11834389 - 81095 3.4.22.1 CID 11834392 - 81093 3.4.22.1 CID 1506381 - 81081 3.4.22.1 CID 2212050 - 81082 3.4.22.1 CID 286532 - 81061 3.4.22.1 CID 2998380 - 81083 3.4.22.1 CID 3236798 - 81084 3.4.22.1 CID 3240114 - 81085 3.4.22.1 CID 3241895 - 81086 3.4.22.1 CID 3243025 - 81087 3.4.22.1 CID 3243128 - 81088 3.4.22.1 CID 3243168 - 81089 3.4.22.1 CID 3250046 - 81090 3.4.22.1 CID 3685806 - 81094 3.4.22.1 CID 5293426 - 81091 3.4.22.1 CID 573353 - 81062 3.4.22.1 CID 646525 - 81063 3.4.22.1 CID 646749 - 81064 3.4.22.1 CID 647501 - 81055 3.4.22.1 CID 647599 - 81065 3.4.22.1 CID 648315 - 81066 3.4.22.1 CID 651936 - 81067 3.4.22.1 CID 653297 - 81054 3.4.22.1 CID 653316 - 81068 3.4.22.1 CID 653862 - 81069 3.4.22.1 CID 654815 - 81070 3.4.22.1 CID 655490 - 81071 3.4.22.1 CID 658111 - 81072 3.4.22.1 CID 658152 - 81073 3.4.22.1 CID 658724 - 81074 3.4.22.1 CID 658964 - 81075 3.4.22.1 CID 660829 - 81076 3.4.22.1 CID 66541 - 81056 3.4.22.1 CID 665480 - 81077 3.4.22.1 CID 714967 - 81078 3.4.22.1 CID 794694 - 81079 3.4.22.1 CID 971438 - 81080 3.4.22.1 citrulline - 1464 3.4.22.1 CLIK148 - 14201 3.4.22.1 CPI-H peptide inhibitor of 13 kDa from rabbit skeletal muscle, noncompetitive 22573 3.4.22.1 CPI-L peptide inhibitor of 23 kDa from rabbit skeletal muscle, noncompetitive 22574 3.4.22.1 Cu2+ - 19 3.4.22.1 Cu2+ 32% residual activity at 1 mM 19 3.4.22.1 Cys (S-benzyl) - 239850 3.4.22.1 CysC natural inhibitor of CatB. CysC deletion in knockout mice leads to an enhanced CatB activity 206275 3.4.22.1 cystatin poor inhibitor, 51% inhibition at 100 nM 1600 3.4.22.1 cystatin Ki: 29 nM 1600 3.4.22.1 cystatin - 1600 3.4.22.1 cystatin binding sequence is FFEYDGVVSGGPYLGK, by mass spectrometric analysis 1600 3.4.22.1 cystatin the enzyme retains 10% and 5% of its initial activity, after 30 min of incubation at 37°C, in the presence of 75 and 100 nM recombinant cystatin, respectively 1600 3.4.22.1 cystatin C Porphyromonas gingivalis interrupts the interaction of cathepsin B with its inhibitor cystatin 1994 3.4.22.1 cystatin C CysC or CST3, an endogenous inhibitor of cysteine proteases, including cathepsin B 1994 3.4.22.1 cystatin C an endogenous inhibitor of cysteine cathepsins, expression patterns of cathepsin B and cystatin C 1994 3.4.22.1 cystatin C - 1994 3.4.22.1 DCG-04 - 24089 3.4.22.1 DCG-04 an E-64-type inhibitor, inhibits both mature cathepsin B and its zymogen 24089 3.4.22.1 di-(2-ethylhexyl)phthalate non-competitive inhibitor 13233 3.4.22.1 diacetato(2-((2dimethylamino)methyl)phenyl)-Au(III) - 75424 3.4.22.1 diaceto[2-[(2-pyridinyl-kappaN)methyl]-phenyl-kappaC]Au(III)- (SP-4-3) - 75427 3.4.22.1 dibutyl phthalate non-competitive inhibitor 18433 3.4.22.1 dichloro(2-((2dimethylamino)methyl)phenyl)Au(III) - 75423 3.4.22.1 dichloro[2-[(2-pyridinyl-kappaN)methyl]phenyl-kappaC]Au(III) - 75426 3.4.22.1 Dimethylsulfoxide - 985 3.4.22.1 doxorubicin - 832 3.4.22.1 E-64 - 559 3.4.22.1 E-64 irreversible inhibition, IC50: 0.000055 mM 559 3.4.22.1 E-64 irreversible inhibitor 559 3.4.22.1 E-64 a cysteine protease inhibitor, inhibition of CmCatB1 559 3.4.22.1 E-64 broad-spectrum cysteine protease inhibitor, complete inhibition 559 3.4.22.1 E-64 a broad cysteine protease inhibitor 559 3.4.22.1 E-64 an irreversible cysteine protease inhibitor 559 3.4.22.1 E-64 inhibition of cathepsin B greatly improves the developmental competence of bovine oocytes and increases the number of high-quality embryos, overview 559 3.4.22.1 E-64 complete inhibition at 1 mM 559 3.4.22.1 E-64 i.e. L-trans-epoxysuccinyl-leucylamido-(4-guanidino)-butane, irreversible inhibitor 559 3.4.22.1 E-64 irreversible covalent inhibitor 559 3.4.22.1 E-64 0.01 mM, 99% loss of activity 559 3.4.22.1 E-64 0.02 mM, complete inhibition; 0.02 mM, complete inhibition; 0.02 mM, complete inhibition; 0.02 mM, complete inhibition 559 3.4.22.1 E-64c irreversible inhibition, IC50: 0.00000870 mM 13400 3.4.22.1 E-64c inhibition of Cathepsin B alone not only reduces hyperthermic injury-induced apoptosis significantly but enhances the beneficial effects of preinduction of HSP-70 in reducing hyperthermic injury-induced apoptosis in H9C2 cells significantly 13400 3.4.22.1 E-64d - 7673 3.4.22.1 E-64d i.e. (L-3-trans-ethoxycarbonyloxirane-2-carbonyl)-L-leucine(3-methylbutyl)amide 7673 3.4.22.1 E64 kinetic analysis 1457 3.4.22.1 E64 kinetics, pH-dependence of inhibition 1457 3.4.22.1 E64 - 1457 3.4.22.1 E64c - 13508 3.4.22.1 E64c the (2S,3S)-3-(L-[N-(3-methylbutyl)amino]leucyl) side chain binds at the S1 and S3 subsites 13508 3.4.22.1 E64d - 18966 3.4.22.1 E64d substituting ethyl(methyl) sulfane for 2-methylbutane (R2) of E64d improves the inhibitory activity and selectivity for cathepsin B inhibition 18966 3.4.22.1 E64d i.e. loxistatin, irreversible covalent inhibitor 18966 3.4.22.1 EDTA 89% remaining activity at 1 mM, 80% remaining activity at 2 mM 21 3.4.22.1 Elastatinal - 8100 3.4.22.1 estatin A irreversible inhibition, IC50: 0.000270 mM 60848 3.4.22.1 estatin B irreversible inhibition, IC50: 0.000320 mM 60849 3.4.22.1 ethoxy-L-trans-epoxysuccinyl-Gly-Pro-OH - 81108 3.4.22.1 ethoxy-L-trans-epoxysuccinyl-Ile-Ala-OH - 81101 3.4.22.1 ethoxy-L-trans-epoxysuccinyl-Ile-Ile-OH - 81102 3.4.22.1 ethoxy-L-trans-epoxysuccinyl-Ile-OH - 81100 3.4.22.1 ethoxy-L-trans-epoxysuccinyl-Thr-Ile-OH - 81103 3.4.22.1 ethyl (1R,2S)-2-([(8-hydroxy-5-nitroquinolin-7-yl)methyl]amino)cyclohexane-1-carboxylate - 205429 3.4.22.1 ethyl (2R,3R)-3-(((1S)-1-[(4-carbamimidamidobutyl)carbamoyl]-3-methylbutyl)carbamoyl)oxirane-2-carboxylate - 129447 3.4.22.1 ethyl (2S,3S)-3-(((1S)-3-methyl-1-[(3-methylbutyl)carbamoyl]butyl)carbamoyl)oxirane-2-carboxylate - 129444 3.4.22.1 ethyl (2S,3S)-3-(((S)-1-((3-fluorophenethyl)amino)-4-(methylthio)-1-oxobutan-2-yl)carbamoyl)oxirane-2-carboxylate - 239834 3.4.22.1 ethyl (2S,3S)-3-(((S)-1-(hexylamino)-4-(methylthio)-1-oxobutan-2-yl)carbamoyl)oxirane-2-carboxylate - 239832 3.4.22.1 ethyl (2S,3S)-3-(((S)-4-(methylthio)-1-oxo-1-((3-phenylpropyl)amino)butan-2-yl)carbamoyl)oxirane-2-carboxylate - 239833 3.4.22.1 ethyl (2S,3S)-3-(((S)-4-(methylthio)-1-oxo-1-((4-phenylbutyl)-amino)butan-2-yl)carbamoyl)oxirane-2-carboxylate - 239836 3.4.22.1 ethyl (2S,3S)-3-(((S)-4-(methylthio)-1-oxo-1-(pentan-3-ylamino)butan-2-yl)carbamoyl)oxirane-2-carboxylate - 239835 3.4.22.1 ethyl 1-(5-nitroquinolin-8-yl)piperidine-4-carboxylate - 205430 3.4.22.1 ethyl 1-[(2R)-2-((1S)-1-(acetyloxy)-2-[((N-[(2,4-difluorophenyl)carbonyl]-L-phenylalanyl)amino)oxy]-2-oxoethyl)pentanoyl]prolinate IC50: 4.4 mM 58438 3.4.22.1 ethyl 3-(5-chloro-3-oxo-1,2-thiazol-2(3H)-yl)propanoate - 86194 3.4.22.1 ethyl 4-[(8-hydroxy-5-nitroquinolin-7-yl)methyl]piperazine-1-carboxylate - 205435 3.4.22.1 EtO-tES-Gly-Pro-OH - 66549 3.4.22.1 EtO-tES-Ile-Ala-OH - 66543 3.4.22.1 EtO-tES-Ile-Ile-OH - 66544 3.4.22.1 EtO-tES-Ile-OH - 66542 3.4.22.1 EtO-tES-Ile-Pro-OH CA-030 66540 3.4.22.1 Fe2+ 79.9% residual activity at 1 mM 25 3.4.22.1 Fe3+ 82.3% residual activity at 1 mM 70 3.4.22.1 Fmoc-Tyr-Ala-CHN2 FYAD, an irreversible inhibitor of cathepsin B, induces apoptosis of neuroblastoma cells but not of other tumor cells. Inhibitors that affect only one enzyme or fail to maintain inhibition of both cathepsins B and L do not induce apoptosis of these cells, overview 160026 3.4.22.1 garciniaphenone a prenylated benzophenone isolated from pericarp hexane extract of dried fruits of Rheedia brasiliensis 160030 3.4.22.1 Gly-Pro-Phe-Pro-Ile amino acids 203-207 of bovine beta-casein, competitive 33793 3.4.22.1 H2O2 - 22 3.4.22.1 heparin inhibition is strongly dependent on pH, no inhibition above pH 7.0 227 3.4.22.1 Hg2+ - 33 3.4.22.1 HIF IC50: 0.00058 mM 60865 3.4.22.1 HNO from Angeli's salt or induced by LPS and IFN-gamma in RAW macrophages, causes DTT-irreversible inhibition and covalently and permanently inactivation of cathepsin B. Cathepsin B activity is reduced to 53%, 25%, and 57% of maximal activity in nonstimulated, LPS-, and IFN-gamma-treated cells, respectively. Endogenous NO production can provide direct protection for the less reactive protein cysteines by scavenging HNO. Additionally, endogenous cellular production of NO can rescue enzyme function by protective nitrosation of cysteines prior to exposure to HNO 75372 3.4.22.1 homophenylalanine - 203466 3.4.22.1 human albutensin A i.e. AFKAWAVAR 117971 3.4.22.1 human cystatin A - 27535 3.4.22.1 human cystatin B - 81059 3.4.22.1 Human cystatin C - 6677 3.4.22.1 IAA - 5162 3.4.22.1 iodoacetamide - 67 3.4.22.1 iodoacetamide concentrations above10 mM significantly decrease activity 67 3.4.22.1 iodoacetic acid - 213 3.4.22.1 iodoacetic acid 100% inhibition at 0.5 mM 213 3.4.22.1 iodoacetic acid complete inhibition at 1 mM 213 3.4.22.1 iodoacetic acid 0.01 mM, partial inhibition; 0.01 mM, partial inhibition; 0.01 mM, partial inhibition; 0.01 mM, partial inhibition 213 3.4.22.1 KI - 1979 3.4.22.1 L-3-carboxy-2,3-trans-epoxypropionyl-leucylamido-(4-guanidino)butane E-64 4903 3.4.22.1 L-3-trans-(propylcarbamoyl)-oxirane-2-carbonyl-L-isoleucyl-L-proline inhibition of cathepsin B decreases the number of active alpha ENaCs in 2F3 cells 206276 3.4.22.1 L-3-trans-(propylcarbamoyl)oxirane-2-carbonyl-L-isoleucyl-L-proline treatment with a cathepsin B inhibitor, leads to transient reduction of local induration, expression of inflammatory cytokines, and subsequent attenuation of the systemic adaptive immune response 206280 3.4.22.1 L-3-trans-(propylcarbamoyl)oxirane-2-carbonyl-L-isoleucyl-L-proline methyl ester activity of caspase 3 is significantly reduced in Dengue virus-infected HepG2 cells treated with cathepsin B or S inhibitor. Treatment with cathepsin B inhibitor also reduces the activity of caspase 9 206274 3.4.22.1 L-3-trans-propylcarbamoyloxirane-2-carbonyl-L-isoleucyl-proline - 206281 3.4.22.1 L-tosylphenylalanylchloromethane - 100815 3.4.22.1 L-trans-epoxysuccinyl-3,5-diiodo-L-tyrosylamido(3-methyl)-butane compound 13b 100817 3.4.22.1 L-trans-epoxysuccinyl-3,5-diiodo-L-tyrosylamido(3-methyl)-butane ethylester compound 13a 100818 3.4.22.1 L-trans-epoxysuccinyl-Ile-Pro-methyl ester complete inhibition at 0.025 mM 139071 3.4.22.1 leupeptin - 217 3.4.22.1 leupeptin 98% inhibition at 1 microM 217 3.4.22.1 leupeptin Ki: 0.15-0.17 nM 217 3.4.22.1 leupeptin 4% remaining activity at 0.010 mM, 1% remaining activity at 0.1 mM 217 3.4.22.1 leupeptin IC50: 0.0000213 mM 217 3.4.22.1 leupeptin 42.5% residual activity at 0.1 mM 217 3.4.22.1 leupeptin leupeptin lacks selectivity since it inhibits both serine and cysteine proteases 217 3.4.22.1 lipopolysaccharides - 6200 3.4.22.1 malonato(2-((2dimethylamino)methyl)phenyl)Au(III) - 75425 3.4.22.1 MeO-Gly-Gly-Leu-NH-tES-Leu-Pro-OH NS-134 139073 3.4.22.1 methoxy-Gly-Gly-L-Leu(2S,3S)-trans-epoxysuccinyl-L-Leu-L-Pro-OH selective for cathepsin B over cathepsin L 117966 3.4.22.1 methyl 3-(4,5-dichloro-3-oxo-1,2-thiazol-2(3H)-yl)propanoate - 86192 3.4.22.1 methyl 3-(5-chloro-3-oxo-1,2-thiazol-2(3H)-yl)propanoate - 86191 3.4.22.1 methyl 3-(5-chloro-4-methyl-3-oxo-1,2-thiazol-2(3H)-yl)propanoate - 86193 3.4.22.1 methyl 4-(5-chloro-3-oxo-1,2-thiazol-2(3H)-yl)butanoate - 86195 3.4.22.1 methyl 6-(3-(propyldisulfanyl)acrylamido)hexanoate - 86446 3.4.22.1 methyl N-([(2R,3R)-3-([(1R)-1-([(2S)-2-carboxypyrrolidin-1-yl]carbonyl)-3-methylbutyl]carbamoyl)oxiran-2-yl]carbonyl)-L-leucylglycylglycinate - 129454 3.4.22.1 methyl N-([(2S,3S)-3-([(1R)-1-([(2S)-2-carboxypyrrolidin-1-yl]carbonyl)-3-methylbutyl]carbamoyl)oxiran-2-yl]carbonyl)-L-leucylglycylglycinate - 129455 3.4.22.1 MG-132 - 10060 3.4.22.1 Mg2+ - 6 3.4.22.1 Mg2+ 50% inhibition at 2 mM 6 3.4.22.1 Miraziridine A irreversible covalent inhibitor 239841 3.4.22.1 mizaridine IC50: 0.00205 mM 60860 3.4.22.1 Mn2+ - 11 3.4.22.1 Mn2+ 10% inhibition at 8 mM, no inhibition at 2 mM 11 3.4.22.1 Mn2+ 85.4% residual activity at 1 mM 11 3.4.22.1 additional information not inhibitory: Z-FY(tert-butyl)-CHN(2) 2 3.4.22.1 additional information analysis of further dipeptidyl nitriles as selective inhibitors 2 3.4.22.1 additional information no inhibition with N-chloroacetyl-Gly-Gly-OH 2 3.4.22.1 additional information no inhibition with pepstatin A at 0.005 and 0.1 mM 2 3.4.22.1 additional information no inhibition of CmCatB1 by PMSF, leupeptin, pepstatin A, ethanol and DMSO 2 3.4.22.1 additional information ruthenium(II)-arene compounds behave as powerful inhibitors 2 3.4.22.1 additional information inhibitory activities of N-cyano-tetrahydro-pyridazine derivatives, docking studies, overview 2 3.4.22.1 additional information inhibitor screening and docking studies to cathepsin B, overview. Predicted bioactivities of inhibitor candidates and molecular mechanics 2 3.4.22.1 additional information the inhibition of cathepsin B causes accumulation of 26-kDa pro-TNF-containing vesicles 2 3.4.22.1 additional information inhibition of cathepsin B by antitumor ruthenium(II)-arene compounds, mechanisms of binding/inhibition, overview 2 3.4.22.1 additional information isolation and identification of a protein inhibitor of cathepsin B from Pseudomonas sp. strain PB01, phylogenetic distribution in Pseudomonas species, overview 2 3.4.22.1 additional information inhibitor screening, overview 2 3.4.22.1 additional information alpha-1-antitrypsin aerosolised augmentation abrogates neutrophil elastase-induced expression of cathepsin B in vivo and in vitro 2 3.4.22.1 additional information design and synthesis of hypervalent tellurium compounds, and irreversible inhibition of cathepsins B by hypervalent tellurium compounds, e.g. organotellurium(IV) compounds, i.e. organotelluranes, that react with thiols forming mixed dichalcogenides, with a tellurium-sulfur bond. Mechanisms for two- and one-step irreversible enzyme inhibition, overview 2 3.4.22.1 additional information no inhibition of cathepsin B by SDF-1 in vivo 2 3.4.22.1 additional information 95-100% enzyme inhibition is required to cause neuroblastoma cell death 2 3.4.22.1 additional information No effects on cathepsin B activity by human chorionic gonadotropin and 17beta-estradiol 2 3.4.22.1 additional information development of cathepsin inhibitors and structure-based design of cathepsin B-specific inhibitor, binding mode at the active site and structure-activity relationship, overview. Quantitative assesment of inhibitor binding at the SN-site of cathepsin B, overview 2 3.4.22.1 additional information screening of pyrimidotriazine-diones and pyrazole sulfonamides as cathepsin B inhibitors, structure-function relationship, overview. Pyrimidotriazine-dione inhibitors, along with several structurally unrelated compounds, are inactive in presence of the reductant cysteine or DTT, thus the inhibitors are acting through a DTT-dependent redox cycling mechanism, rather than through direct inhibition of the enzyme 2 3.4.22.1 additional information correlation between cathepsin B inhibition and cytotoxicity for a series of palladacycles, that show in vitro activity as cytotoxic agents on A2780/S cells and also as cathepsin B inhibitors, synthesis and crystal structure of palladacycles, overview 2 3.4.22.1 additional information growth inhibition of B-16 cells by the palladacycle compounds, overview 2 3.4.22.1 additional information synthesis and screening of organometallic compounds of general formula [(arene)M(PTA)nXm]Y with metal M = Ru2+, Os2+, Rh3+, or Ir3+, and X = Cl or mPTA, and Y = OTf, PF6, for cytotoxicity and ability to inhibit cathepsin B in vitro, overview. Thermodynamics in solution for metal complexes adducts with N-acetyl-L-cysteine-N'-methylamide, inhibitor binding kinetics, structure-function relationship, overview 2 3.4.22.1 additional information cathepsin B inhibitory activity of tetraene lactones from the fungus Talaromyces wortmannii, overview 2 3.4.22.1 additional information no inhibition by human cystatin B 2 3.4.22.1 additional information no inhibition of CatB by soybean cysteine protease inhibitor 2 3.4.22.1 additional information continuous and binary quantitative structure-activity relationship, QSAR, models to classify cathepsin B inhibition activities of small molecules, high throughput screening, detailed overview 2 3.4.22.1 additional information inhibition of cathepsin B increases cell viability in the presence of imatinib 2 3.4.22.1 additional information not inhibited by oryzacystatin-1 N-terminal deletion, reverse mutant 1 (T30I), reverse mutant 2 (Q97L), and reverse mutant 3 (T30I, Q97L) 2 3.4.22.1 additional information not inhibited by dithiothreitol, L-cysteine, EDTA, and EGTA 2 3.4.22.1 additional information concanamycin A is an indirect inhibitor by specific inhibiton of VATPase 2 3.4.22.1 additional information inhibitory potency of a series benzyloxycarbonyl-Phe-X-diazomethylketone, in which Phe promotes binding at S2 while the amino acid X probes S1. The S1 region of cathepsin L also has the ability to accommodate large hydrophobic side chains. In this respect cathepsin L differs from cathepsin B. Thus benzyloxycarbonyl-Phe-Tyr(O-l-butyl)-diazomethylketone, inactivates cathepsin L with higher efficiency compared to cathepsin B 2 3.4.22.1 myricetin - 484 3.4.22.1 N,N-dimethyl-1-(5-nitroquinolin-8-yl)piperidine-3-carboxamide - 205481 3.4.22.1 N-(((2R,3R)-3-[(1-methylethyl)carbamoyl]oxiran-2-yl)carbonyl)-L-leucyl-L-proline - 129467 3.4.22.1 N-(((2S,3S)-3-[(1-methylethyl)carbamoyl]oxiran-2-yl)carbonyl)-L-leucyl-L-proline - 129468 3.4.22.1 N-((1S)-2-[(2R,3R)-2-[(benzyloxy)carbonyl]-3-(ethoxycarbonyl)aziridin-1-yl]-1-methyl-2-oxoethyl)-Na-(tert-butoxycarbonyl)-L-phenylalaninamide - 129477 3.4.22.1 N-(1-cyanocyclopropyl)-8-hydroxy-5-nitroquinoline-7-carboxamide - 234982 3.4.22.1 N-(3-carboxy-1,2,4-thiadiazolidin-5-yl)-L-leucyl-L-proline IC50: 0.300 mM 58427 3.4.22.1 N-(3-methoxy-1,2,4-thiadiazolidin-5-yl)-L-leucyl-L-proline IC50: 0.0026 mM 58424 3.4.22.1 N-(3-methyl-1,2,4-thiadiazolidin-5-yl)-L-leucyl-L-proline IC50: 0.447 mM 58426 3.4.22.1 N-(3-phenyl-1,2,4-thiadiazolidin-5-yl)-L-leucyl-L-proline IC50: 0.074 mM 58425 3.4.22.1 N-(cyanomethyl)-5-nitroquinoline-8-carboxamide - 234988 3.4.22.1 N-(cyanomethyl)-8-hydroxy-5,7-dinitroquinoline-2-carboxamide - 234993 3.4.22.1 N-(cyanomethyl)-8-hydroxy-5-nitroquinoline-7-carboxamide - 234981 3.4.22.1 N-(L-3-trans-carboxyoxirane-2-carbonyl)-Ile-Pro CA-030 100962 3.4.22.1 N-(L-3-trans-carboxyoxirane-2-carbonyl)-L-leucylamino-3-methylbutane E64c 66539 3.4.22.1 N-(L-3-trans-propylcarbamoyloxirane-2-carbonyl)-Ile-Pro CA-074 47364 3.4.22.1 N-(L-3-trans-propylcarbamoyloxirane-2-carbonyl)-L-isoleucyl-L-proline CA-074 13947 3.4.22.1 N-(L-3-trans-propylcarbamoyloxirane-2-carbonyl)-L-isoleucyl-L-proline CA-074; CA-074; CA-074; CA-074 13947 3.4.22.1 N-(L-3-trans-propylcarbamoyloxirane-2-carbonyl)-L-isoleucyl-L-proline CA-074, 40.4% inhibition at 0.010 mM in cell lysates 13947 3.4.22.1 N-(L-3-trans-propylcarbonyl-oxirane-2-carbonyl)-L-isoleucyl-L-proline i.e. CA074, a cathepsin B-selective inhibitor 39044 3.4.22.1 N-(L-3-trans-propylcarbonyl-oxirane-2-carbonyl)-L-isoleucyl-L-proline i.e. CA074 39044 3.4.22.1 N-(L-3-trans-propylcarbonyl-oxirane-2-carbonyl)-L-isoleucyl-L-proline methyl ester i.e. CA074Me, inhibits the enzyme and PANC-1 cellular invasiveness, overview 39043 3.4.22.1 N-(L-3-trans-propylcarbonyl-oxirane-2-carbonyl)-L-isoleucyl-L-proline methyl ester i.e. CA074Me, a cathepsin B-selective inhibitor 39043 3.4.22.1 N-(L-3-trans-propylcarbonyl-oxirane-2-carbonyl)-L-isoleucyl-L-proline methyl ester i.e. CA074Me 39043 3.4.22.1 N-(trans-epoxysuccinyl)-L-leucine 4-guanidinobutylamide addition of E-64 significantly decreases the activities of cathepsin B and caspase 3, and TUNEL-positive cells in heat-shocked in vitro maturated (IVM) bovine cumulus-oocyte complexes. Addition of inhibitor during in vitro maturation under heat shock conditions significantly improves both developmental competence and quality of the produced embryos 206268 3.4.22.1 N-([(2R,3R)-1-[N-(tert-butoxycarbonyl)-L-phenylalanyl]-3-(ethoxycarbonyl)aziridin-2-yl]carbonyl)-L-leucyl-L-proline - 129475 3.4.22.1 N-([(2R,3R)-3-((5-amino-1-[(4-carbamimidamidobutyl)carbamoyl]pentyl)carbamoyl)oxiran-2-yl]carbonyl)-L-leucyl-L-proline - 129469 3.4.22.1 N-([(2R,3R)-3-(butoxycarbonyl)oxiran-2-yl]carbonyl)-L-leucyl-L-proline - 129466 3.4.22.1 N-([(2R,3R)-3-(ethoxycarbonyl)oxiran-2-yl]carbonyl)-L-leucyl-L-arginine - 129445 3.4.22.1 N-([(2R,3R)-3-(ethoxycarbonyl)oxiran-2-yl]carbonyl)-L-leucyl-L-proline - 129463 3.4.22.1 N-([(2R,3R)-3-([(1R)-1-([(2S)-2-carboxypyrrolidin-1-yl]carbonyl)-3-methylbutyl]carbamoyl)oxiran-2-yl]carbonyl)-L-leucylglycyl-N-(6-[((2-[6-(diethylamino)-3-(diethyliminio)-3H-xanthen-9-yl]phenyl)carbonyl)amino]hexyl)glycinamide - 129456 3.4.22.1 N-([(2R,3R)-3-([(1R)-1-([(2S)-2-carboxypyrrolidin-1-yl]carbonyl)-3-methylbutyl]carbamoyl)oxiran-2-yl]carbonyl)-L-leucylglycyl-N-[6-((5-[(4R)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl)amino)hexyl]glycinamide - 129457 3.4.22.1 N-([(2R,3R)-3-carboxyoxiran-2-yl]carbonyl)-L-leucyl-L-arginine - 129446 3.4.22.1 N-([(2R,3R)-3-carboxyoxiran-2-yl]carbonyl)-L-leucyl-L-proline - 129461 3.4.22.1 N-([(2S,3S)-1-[N-(tert-butoxycarbonyl)-L-phenylalanyl]-3-(ethoxycarbonyl)aziridin-2-yl]carbonyl)-L-leucyl-L-proline - 129476 3.4.22.1 N-([(2S,3S)-3-((5-amino-1-[(4-carbamimidamidobutyl)carbamoyl]pentyl)carbamoyl)oxiran-2-yl]carbonyl)-L-leucyl-L-proline - 129470 3.4.22.1 N-([(2S,3S)-3-(ethoxycarbonyl)oxiran-2-yl]carbonyl)-L-leucyl-L-proline - 129464 3.4.22.1 N-([(2S,3S)-3-carboxyoxiran-2-yl]carbonyl)-L-leucyl-L-leucine - 129452 3.4.22.1 N-([(2S,3S)-3-carboxyoxiran-2-yl]carbonyl)-L-leucyl-L-proline - 129462 3.4.22.1 N-acetyl-3,5-diphenyl pyrazolines - 205560 3.4.22.1 N-acetyl-5-(4-bromophenyl)-3-phenyl-2-pyrazoline - 205561 3.4.22.1 N-acetyl-5-(4-chlorophenyl)-3-phenyl-2-pyrazoline - 205562 3.4.22.1 N-acetyl-5-(4-methoxyphenyl)-3-phenyl-2-pyrazoline - 205563 3.4.22.1 N-acetyl-5-(4-methylphenyl)-3-phenyl-2-pyrazoline - 205564 3.4.22.1 N-acetyl-5-(4-nitrophenyl)-3-phenyl-2-pyrazoline - 205565 3.4.22.1 N-Acetyl-Leu-Leu-methional reversible inhibitor 94215 3.4.22.1 N-alpha-[(benzyloxy)carbonyl]-N-[(3S)-1-[(2,6-dimethylbenzoyl)oxy]-7-[(6-[(2Z)-2-[(2E,4E)-5-(1-ethyl-3,3-dimethyl-5-sulfo-3H-indolium-2-yl)penta-2,4-dien-1-ylidene]-3,3-dimethyl-5-sulfo-2,3-dihydro-1H-indol-1-yl]hexanoyl)amino]-2-oxoheptan-3-yl]-L-phenylalaninamide - 206279 3.4.22.1 N-benzoyl-3,5-diphenylpyrazoline - 201775 3.4.22.1 N-benzoyl-5-(2-chloro phenyl)-3-phenylpyrazoline - 206269 3.4.22.1 N-benzoyl-5-(2-methoxyphenyl)-3-phenylpyrazoline - 201779 3.4.22.1 N-benzoyl-5-(2-nitrophenyl)-3-phenylpyrazoline - 201782 3.4.22.1 N-benzoyl-5-(3-chloro phenyl)-3-phenylpyrazoline - 206270 3.4.22.1 N-benzoyl-5-(3-methoxy phenyl)-3-phenylpyrazoline - 206272 3.4.22.1 N-benzoyl-5-(3-nitrophenyl)-3-phenylpyrazoline - 201783 3.4.22.1 N-benzoyl-5-(4-chloro phenyl)-3-phenylpyrazoline - 206271 3.4.22.1 N-benzoyl-5-(4-methoxy phenyl)-3-phenylpyrazoline - 206273 3.4.22.1 N-benzoyl-5-(4-nitrophenyl)-3-phenylpyrazoline - 201784 3.4.22.1 N-benzyl-5-nitroquinolin-8-amine - 205566 3.4.22.1 N-benzyl-N,N-diethylethanaminium 1-trichloro-4-chloro-2,3-dihydro-2-oxatellurophene - 160013 3.4.22.1 N-benzyl-N,N-diethylethanaminium 2,2,2,4-tetrachloro-2,5-dihydro-2lambda6-[1,2]-oxatellurolinate complex - 129488 3.4.22.1 N-benzyl-N-(cyanomethyl)-8-hydroxy-5,7-dinitroquinoline-2-carboxamide - 234992 3.4.22.1 N-benzyl-N-(cyanomethyl)-8-hydroxy-5-nitroquinoline-2-carboxamide - 234987 3.4.22.1 N-benzyl-N-(cyanomethyl)-8-hydroxy-5-nitroquinoline-7-carboxamide - 234980 3.4.22.1 N-benzyl-N-methyl-5-nitroquinolin-8-amine - 205568 3.4.22.1 N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone - 40405 3.4.22.1 N-chloroacetyl-Gly-Leu-OH - 132499 3.4.22.1 N-chloroacetyl-Leu-Leu-OH - 132502 3.4.22.1 N-chloroacetyl-Leu-Leu-OMe - 132503 3.4.22.1 N-chloroacetyl-Lys-Leu-OH - 132498 3.4.22.1 N-chloroacetyl-Phe-Leu-OH - 132500 3.4.22.1 N-chloroacetyl-Phe-Met-OH - 132501 3.4.22.1 N-chloroacetyl-Ser-Leu-OH - 132497 3.4.22.1 N-ethylmaleimide no inhibition at 1 mM 49 3.4.22.1 N-ethylmaleimide - 49 3.4.22.1 N-ethylmaleimide concentrations above10 mM significantly decrease activity 49 3.4.22.1 N-formyl-3,5-diphenylpyrazoline - 201765 3.4.22.1 N-formyl-5-(2-chlorophenyl)-3-phenylpyrazoline - 201766 3.4.22.1 N-formyl-5-(2-methoxyphenyl)-3-phenylpyrazoline - 201769 3.4.22.1 N-formyl-5-(2-nitrophenyl)-3-phenylpyrazoline - 201772 3.4.22.1 N-formyl-5-(3-chlorophenyl)-3-phenylpyrazoline - 201767 3.4.22.1 N-formyl-5-(3-methoxyphenyl)-3-phenylpyrazoline - 201770 3.4.22.1 N-formyl-5-(3-nitrophenyl)-3-phenylpyrazoline - 201773 3.4.22.1 N-formyl-5-(4-chlorophenyl)-3-phenylpyrazoline - 201768 3.4.22.1 N-formyl-5-(4-methoxyphenyl)-3-phenylpyrazoline - 201771 3.4.22.1 N-formyl-5-(4-nitrophenyl)-3-phenylpyrazoline - 201774 3.4.22.1 N-p-tosylphenyl-L-lysine-chloromethane - 101139 3.4.22.1 N-phenyl-3-(propyldisulfanyl)-3-chloro-acrylamide - 86448 3.4.22.1 N-phenyl-3-(propyldisulfanyl)acrylamide - 86445 3.4.22.1 n-propyl-(2S,3S)-trans-epoxysuccinyl-L-Ile-OH kinetic analysis 117970 3.4.22.1 N-tosyl-lysyl chloromethylketone - 6690 3.4.22.1 N-tosyl-phenylalanine chloromethylketone - 31587 3.4.22.1 N-[(1E,3S)-5-phenyl-1-(phenylsulfonyl)pent-1-en-3-yl]-L-norvalinamide - 7040 3.4.22.1 N-[(1R)-1-cyano-2-([3-(2H-tetrazol-2-yl)benzyl]oxy)ethyl]-3-methyl-Na-(3-oxo-1,3-dihydro-2-benzofuran-5-yl)-L-phenylalaninamide IC50: 0.000005 mM 58459 3.4.22.1 N-[(1S)-3-(benzyloxy)-1-cyanopropyl]-Nalpha-(diphenylacetyl)-3-methyl-L-phenylalaninamide IC50: 0.0000102 mM 58450 3.4.22.1 N-[(3-methoxy-1,2,4-thiadiazolidin-5-yl)carbamoyl]-L-leucyl-L-proline IC50: 0.390 mM 58428 3.4.22.1 N-[2-[(3-carboxyphenyl)methoxy]-1-(S)-cyanoethyl]-3-methyl-Nalpha-(2,4-difluorobenzoyl)-L-phenylalaninamide 50% inhibition at 6.8 nM, selective for cathepsin B 117958 3.4.22.1 N-[[1-(1,3-benzothiazol-2-yl)piperidin-3-yl]methyl]-8-hydroxy-5-nitroquinoline-7-carboxamide - 239838 3.4.22.1 N-[[1-(1,3-benzoxazol-2-yl)piperidin-3-yl]methyl]-8-hydroxy-5-nitroquinoline-7-carboxamide - 234983 3.4.22.1 N2-(morpholin-4-ylcarbonyl)-N-[(1E,3S)-5-phenyl-1-(phenylsulfonyl)pent-1-en-3-yl]-L-leucinamide - 7041 3.4.22.1 Na-[(benzyloxy)carbonyl]-N-(3-methoxy-1,2,4-thiadiazolidin-5-yl)-L-phenylalaninamide IC50: 0.021 mM 58430 3.4.22.1 Nalpha-(tert-butoxycarbonyl)-N-((1S)-2-[(2R,3R)-2-carboxy-3-(ethoxycarbonyl)aziridin-1-yl]-1-methyl-2-oxoethyl)-L-phenylalaninamide - 129478 3.4.22.1 Nalpha-[(benzyloxy)carbonyl]-N-[(2R,3S)-2-(carboxyoxy)-4-oxoazetidin-3-yl]-L-phenylalaninamide IC50: 0.00047 mM 58433 3.4.22.1 Nalpha-[(benzyloxy)carbonyl]-N-[(3S,4R)-2-oxo-4-phenoxyazetidin-3-yl]-L-phenylalaninamide IC50: 0.00043 mM 58432 3.4.22.1 Nalpha-[(benzyloxy)carbonyl]-N-[(5R,6R)-4,4-dioxido-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-L-phenylalaninamide IC50: 0.00035 mM 58435 3.4.22.1 Nalpha-[(benzyloxy)carbonyl]-N-[(5R,6R)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-L-phenylalaninamide IC50: more than 0.00050 mM 58436 3.4.22.1 Nalpha-[(benzyloxy)carbonyl]-N-[(5R,6S)-7-oxo-4-oxa-1-azabicyclo[3.2.0]hept-6-yl]-L-phenylalaninamide IC50: 0.00176 mM 58434 3.4.22.1 Nalpha-[(benzyloxy)carbonyl]-N-[(6R)-4-oxido-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-L-phenylalaninamide IC50: 0.0164 mM 58437 3.4.22.1 NAMI-A i.e. [imidazoleH][trans-Ru(DMSO)(imidazole)Cl4], an antimetastatic compound 159999 3.4.22.1 NC-2300 i.e. monosodium (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylate, a cysteine cathepsin inhibitor 10223 3.4.22.1 Ni2+ 26.7% residual activity at 1 mM 38 3.4.22.1 NO - 277 3.4.22.1 NS-196 0.0005 mM 139069 3.4.22.1 oryzacystatin-1 - 86441 3.4.22.1 oryzacystatin-1 clone A10 - 86444 3.4.22.1 Os(II)-pentamethylcyclopentadienyl 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane N-acetyl-L-cysteine-N'-methylamide i.e. OSPTAC 160001 3.4.22.1 oxalo-RAPTA ruthenium(II)-arene compound 75379 3.4.22.1 oxidized glutathione concentrations above10 mM significantly decrease activity 1794 3.4.22.1 p-chloromercuribenzoate - 43 3.4.22.1 p-chloromercuriphenyl sulfonic acid - 2753 3.4.22.1 p-hydroxymercuribenzoate - 98 3.4.22.1 Pefabloc SC 1.0 mM, 11% loss of activity 5680 3.4.22.1 penetratin - 22572 3.4.22.1 penetratin HP-CO-(CH2)5-NH-Gly-Gly-L-Leu(2S,3S)-trans-epoxysuccinyl-L-Leu-L-Pro-OH selective for cathepsin B over cathepsin L, penetratin moiety allows penetration of cell membrane, almost complete inactivation at 300 nM, at 10 nM block of about 60% of intracellular enzyme activity 117969 3.4.22.1 Peptidyl chloromethylketones - 97327 3.4.22.1 peptidyl cyclopropenone reversible inhibitor 239845 3.4.22.1 peptidyl diazomethyl ketone derivatives - 47443 3.4.22.1 peptidyl diazomethyl ketone derivatives peptidyl diazomethanes 47443 3.4.22.1 phenylacetyl hydrazine competitive inhibition 201798 3.4.22.1 phenylmethanesulfonyl fluoride no inhibition at 0.1 mM 827 3.4.22.1 phenylmethanesulfonyl fluoride 27-33% inhibition at 0.5 mM 827 3.4.22.1 phenylmethanesulfonyl fluoride 18% inhibition in the presence of 10 microM 827 3.4.22.1 phenylmethanesulfonyl fluoride no inhibition at 10 microM 827 3.4.22.1 phenylmethanesulfonyl fluoride no inhibition at 0.5 mM 827 3.4.22.1 phenylmethylsulfonyl fluoride 62.8% residual activity at 1 mM 257 3.4.22.1 PMSF 98% remaining activity at 0.5 mM, 93% remaining activity at 1 mM 248 3.4.22.1 PMSF 2 mM, partial inhibition; 2 mM, partial inhibition; 2 mM, partial inhibition; 2 mM, partial inhibition 248 3.4.22.1 PrnNH-tES-Ile-Pro-OBzl - 66547 3.4.22.1 PrnNH-tES-Ile-Pro-OH CA-074 66541 3.4.22.1 PrnNH-tES-Ile-Pro-OMe - 66546 3.4.22.1 Pro-Phe-Pr-Gly-Pro-Ile amino acids 61-66 of bovine beta-casein, competitive 54338 3.4.22.1 propylcarbonyl-L-trans-epoxysuccinyl-Ile-O-benzyl ester - 81106 3.4.22.1 propylcarbonyl-L-trans-epoxysuccinyl-Ile-Pro-O-methyl ester - 81105 3.4.22.1 Proteinase inhibitors from potato tuber 20973 3.4.22.1 Proteinase inhibitors from rat, human, tuna fish, toad, chicken 20973 3.4.22.1 Proteinase inhibitors from chickenīs egg white 20973 3.4.22.1 PRT2005 commercial peptidyl ketone inhibitors, Prototek, 50% inhibition at less than 0.001 mM 117959 3.4.22.1 PRT2253 commercial peptidyl ketone inhibitors, Prototek, 50% inhibition at less than 0.001 mM 117960 3.4.22.1 quercetin - 137 3.4.22.1 RAPTA-BC ruthenium(II)-arene compound 75376 3.4.22.1 RAPTA-BI ruthenium(II)-arene compound 75384 3.4.22.1 RAPTA-C i.e. carbo-RAPTA, ruthenium(II)-arene compound 75375 3.4.22.1 RAPTA-H ruthenium(II)-arene compound 75380 3.4.22.1 RAPTA-Me+C ruthenium(II)-arene compound 75378 3.4.22.1 RAPTA-NH3 ruthenium(II)-arene compound 75383 3.4.22.1 RAPTA-OH ruthenium(II)-arene compound 75374 3.4.22.1 RAPTA-pentaOH binding structure from cyrstal structure of the inhibitor bound to cathepsin B, overview 75377 3.4.22.1 RAPTA-T ruthenium(II)-arene compound 75373 3.4.22.1 RAPTA-TBMe ruthenium(II)-arene compound 75381 3.4.22.1 RAPTA-TBOH ruthenium(II)-arene compound 75382 3.4.22.1 rhodamine B-NH-(CH2)6-NH-Gly-Gly-L-Leu(2S,3S)-trans-epoxysuccinyl-L-Leu-L-Pro-OH selective for cathepsin B over cathepsin L 117967 3.4.22.1 RNA interference oligonucleotide shRNA-CTSB2 most efficient inhibition of cathepsin B at both mRNA and protein levels and results in suppressing endometrial cancer growth and development in vivo 239839 3.4.22.1 Ru(II)-pentamethylcyclopentadienyl 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane N-acetyl-L-cysteine-N'-methylamide i.e. RAPTA-C 81044 3.4.22.1 Ser-(O-benzyl) - 239849 3.4.22.1 sheep cystatin B - 27536 3.4.22.1 sodium chloro[[4,4',4''-(phosphinidyne-kappaP)tris[benzenesulfonato]]aurate] - 66026 3.4.22.1 Soybean trypsin inhibitor 51.2% residual activity at 0.1 g/l 544 3.4.22.1 stefin-1 - 239830 3.4.22.1 stefin-2 - 239831 3.4.22.1 tert-butyl ([1-[(2-cyanotetrahydropyridazin-1(2H)-yl)carbonyl]-2-methylpropyl]carbamoyl)carbamate - 26160 3.4.22.1 Thr (O-tert-butyl) - 239852 3.4.22.1 TMC-52A irreversible inhibition, IC50: 0.000320 mM 60853 3.4.22.1 TMC-52B irreversible inhibition, IC50: 0.000200 mM 60854 3.4.22.1 TMC-52C irreversible inhibition, IC50: 0.000460 mM 60855 3.4.22.1 TMC-52D irreversible inhibition, IC50: 0.000280 mM 60856 3.4.22.1 tokaramide A IC50: 0.0000624 mM 60861 3.4.22.1 TPCK 0.2 mM, partial inhibition; 0.2 mM, partial inhibition; 0.2 mM, partial inhibition; 0.2 mM, partial inhibition 7403 3.4.22.1 trans-cis-cis-[RuCl2(DMSO)2(2-amino-5-methyl-thiazole)2] i.e. (PMRu52), a ruthenium(II) compound acting as a strong inhibitor of cathepsin B, crystal structure and binding structure analysis, overview 81060 3.4.22.1 trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane E-64, 43% remaining activity at 0.005 mM, 32% remaining activity at 0.020 mM, 2% remaining activity at 0.030 mM 8202 3.4.22.1 trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane E-64 8202 3.4.22.1 trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane E-64; E-64; E-64 8202 3.4.22.1 trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane E-64, 63.2% inhibition at 0.010 mM in cell lysates 8202 3.4.22.1 trans-epoxysuccinyl-L-leucyl-smido(4-guanidino)butane E-64 132506 3.4.22.1 trans-epoxysuccinyl-leucylamido(4-guanidino)butane - 81050 3.4.22.1 trichloro(dioxoethylene-O,O')tellurate - 160002 3.4.22.1 triethylphosphine(2,3,4,6-tetra-O-acetyl-beta-1-D-thiopyranosato-S)gold(I) auranofin 139070 3.4.22.1 Trp inactivation rate is 12 mM/min 817 3.4.22.1 Tyr-(O-methyl) inactivation rate is 1.548 mM/min 239848 3.4.22.1 Tyr-(O-tert-butyl) inactivation rate is 0.618 mM/min 239847 3.4.22.1 Urea inactivated at 3 M 116 3.4.22.1 WF14861 irreversible inhibition, IC50: 0.000016 mM 60859 3.4.22.1 WF14865A irreversible inhibition, IC50: 0.0000084 mM 60857 3.4.22.1 WF14865B irreversible inhibition, IC50: 0.000013 mM 60858 3.4.22.1 wortmannilactone E i.e. (19S)-(4S,7R)-7-[(1E,3E,5E,7E)-8-[(2S,5S,6S)-5,6-dihydro-5-hydroxy-3,5,6-trimethyl-2H-pyran-2-yl]nona-1,3,5,7-tetraen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione, isolated from the culture medium of the soil filamentous fungus Talaromyces wortmannii, Chuxiong, Yunnan Province, China. Determination of structure and relative configuration by 1D- and 2D-NMR techniques, overview 81096 3.4.22.1 wortmannilactone F i.e. (19R)-(4S,7R)-7-[(1E,3E,5E,7E)-8-[(2S,5R,6S)-5,6-dihydro-5-hydroxy-3,5,6-trimethyl-2H-pyran-2-yl]nona-1,3,5,7-tetraen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione, isolated from the culture medium of the soil filamentous fungus Talaromyces wortmannii, Chuxiong, Yunnan Province, China. Determination of structure and relative configuration by 1D- and 2D-NMR techniques, overview 81097 3.4.22.1 wortmannilactone G i.e. methyl (2R)-2-[(3R,4R)-3-[(1E,3E,5E,7E)-8-[(2S,3R,6S)-3,6-dihydro-3-hydroxy-3,5,6-trimethyl-2H-pyran-2-yl]nona-1,3,5,7-tetraen-1-yl]-3,4-dimethyl-5-oxotetrahydrofuran-2-yl]propanoate, isolated from the culture medium of the soil filamentous fungus Talaromyces wortmannii, Chuxiong, Yunnan Province, China. Determination of structure and relative configuration by 1D- and 2D-NMR techniques, overview 81098 3.4.22.1 wortmannilactone H i.e. (4S,7R)-7-[(1E,3E,5E,7E)-8-[(2S,3R,6S)-3,6-dihydro-3-hydroxy-3,6-dimethyl-2H-pyran-2-yl]nona-1,3,5,7-tetraen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione, isolated from the culture medium of the soil filamentous fungus Talaromyces wortmannii, Chuxiong, in Chinas Yunnan Province. Determination of structure and relative configuration by 1D- and 2D-NMR techniques, overview 81099 3.4.22.1 YM 51084 IC50: 0.000012 mM 60862 3.4.22.1 Z-Arg-Gly-Pro-Agly-Gly-Glu-OMe - 60869 3.4.22.1 Z-Arg-Leu-Arg-alpha-aza-glycyl-Ile-Val-OMe i.e. ZRLR, a highly selective cathepsin B inhibitor, cell-permeable, almost complete inhibition at 0.0001 mM 160024 3.4.22.1 Z-Arg-Leu-His-Agly-Ile-Val-OMe - 60866 3.4.22.1 Z-Arg-Leu-Phe-Agly-Val-Ala-OMe - 60871 3.4.22.1 Z-Arg-Leu-Val-Agly-Gly-Asp-OMe - 60870 3.4.22.1 Z-Arg-Leu-Val-Agly-Gly-Glu-OMe - 60867 3.4.22.1 Z-Arg-Leu-Val-Agly-Ser-Ala-OMe - 132505 3.4.22.1 Z-Arg-Nle-Pro-Agly-Gly-Glu-OMe - 132504 3.4.22.1 Z-Arg-Nle-Val-Agly-Gly-Glu-OMe - 60868 3.4.22.1 Z-Phe-Ala-CH2-O-CO-(2,4,6-trimethyl)-Ph - 129485 3.4.22.1 Z-Phe-Ala-CH2-O-CO-(2,5-(CF3)2)-Ph - 129487 3.4.22.1 Z-Phe-Ala-CH2-O-CO-(2,6-(CF3)2)-Ph - 129483 3.4.22.1 Z-Phe-Cys(SBzl)-CH2-O-CO-(2,6-(CF3)2)-Phe - 129486 3.4.22.1 Z-Phe-Gly-NHO-Bz an inhibitor of both cathepsins B and L, causes death of many cell types 160027 3.4.22.1 Z-Phe-Lys-CH2-O-CO-(2,4,6-trimethyl)-Ph - 129484 3.4.22.1 Zn2+ - 14 3.4.22.1 Zn2+ 80% inhibition at 2 mM 14 3.4.22.1 Zn2+ 14.7% residual activity at 1 mM 14 3.4.22.1 [(1-methyl-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one)PdCl]2 - 160017 3.4.22.1 [(1-methyl-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one)Pd(1,3,5-triaza-7-phosphaadamantane)Cl] - 81058 3.4.22.1 [(1-methyl-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one)Pd(1,3,5-triaza-7-phosphoadamantane)Cl] - 160016 3.4.22.1 [(benzyl(methyl)sulfane)Pd(1,3,5-triaza-7-phosphaadamantane)Cl] - 40406 3.4.22.1 [(N,N-dimethyl-1-phenylmethanamine)Pd(1,3,5-triaza-7-phosphaadamantane)Cl] - 81057 3.4.22.1 [(N,N-dimethyl-1-phenylmethanamine)Pd(1,3,5-triaza-7-phosphoadamantane)Cl] - 160015 3.4.22.1 [1-(2-cyano-tetrahydro-pyridazine-1-carbonyl)-2-methyl-propyl]-carbamic acid benzyl ester - 26161 3.4.22.1 [2-(1-benzyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-5-yl-kN4)phenyl-kC1](chloro)(pyridine)palladium(1+) - 160022 3.4.22.1 [2-(1-benzyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-5-yl-kN4)phenyl-kC1](chloro)(triphenylphosphane)palladium(1+) - 160023 3.4.22.1 [2-(mercapto-kappaS)benzoato(2-)-kappaO][2-[(2-pyridinyl-kappaN)methyl]phenyl-kappaC]Au(III) - 75428 3.4.22.1 [2-[2-(2,4-dioxo-1,3-thiazolidin-3-yl)ethylamino]-2-oxoethyl] 2-(furan-2-carbonylamino) acetate i.e. DOFA, a reversible, double-headed competitive inhibitor of cathepsin B, the dioxothiazolidine head of the compound sterically hinders binding of the C-terminal residue of substrates resulting in inhibition of the exopeptidase activity of cathepsin B in a physiopathologically relevant pH range, competitive versus substrates ortho-aminobenzoyl-Gly-Ile-Val-Arg-Ala-Lys-Nepsilon-2,4-dinitrophenyl-OH and carbobenzoxy-Arg-Arg-7-amido-4-methylcoumarin, structure and enzyme docking, overview 26162 3.4.22.1 [imidazoleH][trans-Ru(imidazole)2Cl4] i.e. KP1019 160000 3.4.22.1 [Ir(III)-pentamethylcyclopentadienyl-(1,3,5-triaza-7-phospatatricyclo[3.3.1.1]decane)Cl2] - 81048 3.4.22.1 [Ir(III)-pentamethylcyclopentadienyl-(1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane)2Cl]PF6 - 81045 3.4.22.1 [Ir(III)-pentamethylcyclopentadienyl-methyl(1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane)Cl2]OTf - 81046 3.4.22.1 [Ir(III)-pentamethylcyclopentadienyl-methyl(1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane)Cl](OTf)PF6 - 81047 3.4.22.1 [L-3-trans-(propylcarbamoyl)oxirane-2-carbonyl]-L-isoleucyl-L-proline - 139078 3.4.22.1 [L-3-trans-(propylcarbamoyl)oxirane-2-carbonyl]-L-isoleucyl-L-proline methyl ester CA-074-Me, specific inhibitor 139080 3.4.22.1 [N-(L-3-trans-propylcarbamoyl oxirane-2-carbonyl)-L-isoleucyl-L-proline] specific inhibitor 139079 3.4.22.1 [N-benzyl-N,N-diethylethanaminium]2 hexachloro-lambda6-tellane - 81053 3.4.22.1 [Pd2((R)-3-isopropyl-1-methyl-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one)2(m-1,1'-bis(diphenylphosphino)ferrocene)Cl2] - 40411 3.4.22.1 [Pd2((R)-3-isopropyl-1-methyl-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one)2(m-1,2-bis(diphenylphosphino)ethane)Cl2] - 40408 3.4.22.1 [Pd2((S)-3-isopropyl-1-methyl-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one)2(m-1,2-bis(diphenylphosphino)ethane)Cl2] - 40409 3.4.22.1 [Pd2(1-methyl-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one)2(m-1,2-ethanebis(diphenylphosphine))Cl2] structure analysis by NMR spectroscopy and in the solid state by X-ray crystallography; structure analysis by NMR spectroscopy and in the solid state by X-ray crystallography. It inhibits cathepsin B, and also K562 leukemia cells with an IC50 value of 0.0043 mM after 1 h exposure 40412 3.4.22.1 [Pd2(1-methyl-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one)2(m-1,1'-bis(diphenylphosphino)ferrocene)Cl2] - 40410 3.4.22.1 [Pd2(1-methyl-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one)2(m-1,2-bis(diphenylphosphino)ethane)Cl2] - 40407 3.4.22.1 [Ru(II)-pentamethylcyclopentadienyl-(1,3,5-triaza-7-phosphatatricyclo[3.3.1.1]decane)Cl2] - 81049